| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim CFO and Secretary | Chief Financial Officer | CFO (interim)
3 companies
Christopher S Downs is Chief Financial Officer at CNSP, with reported holdings spanning 3 companies. Christopher S Downs's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $853K at current prices.
Our model assigns Christopher S Downs a below-average insider score of 17/100, based on 5 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -93.0%.
Christopher S Downs's largest disclosed position is in CNSP as Chief Financial Officer, worth about $471K. Net of sales, the CNSP filings show accumulation of 248,266 shares.
Christopher S Downs has 20 Form 4 filings on record from August 2016 to October 2026, across 3 companies: Interim CFO and Secretary at Vertical Data (VDTA), 2026; Chief Financial Officer at CNS Pharmaceuticals (CNSP), 2019–2025; Executive Vice President at InfuSystem (INFU), 2016–2017.
The 24 reported transactions were 12 option or other derivative awards, 7 open-market purchases, 4 stock awards and 1 option exercise.
Counted by filing, the open-market trades come to 7 purchases worth about $379K and no sales.
The largest open-market purchase was 142,000 shares of CNSP at an average $2.04 on August 24, 2020, about $290K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 66,666 | $0.30 | $19,999.80 | +181.3% | -13.7% | -99.2% | |
| Aug 22, 2023 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 27,000 | $1.27 | $34,176.60 | +276.3% | +41.4% | -99.8% | |
| Apr 17, 2023 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 3,100 | $3.20 | $9,920.00 | +50.4% | -22.2% | -92.4% | |
| Dec 6, 2021 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 5,000 | $0.94 | $4,701.50 | +3.4% | -71.7% | -91.1% | |
| Nov 19, 2021 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 4,500 | $1.15 | $5,191.65 | +3.2% | -70.9% | -82.5% | |
| Aug 24, 2020 | CNSP Cns Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 142,000 | $2.04 | $289,680.00 | New | - | - | |
| Aug 14, 2017 | INFU Infusystem Holdings, Inc | CFO (interim) | Buy | 7,900 | $1.90 | $15,010.00 | +37.7% | - | - |